Free tool
FAERS Monitor: Proair Respiclick
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205636 or its brand name (Proair Respiclick, Albuterol Sulfate). Reports on generic versions are filed under their own applications.
Reports
93,526
Serious
37,173
40% of reports
Hospitalization
18,831
Death reported
4,121
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea13,701
- wrong technique in product usage process11,012
- no adverse event8,682
- device delivery system issue8,121
- drug dose omission by device7,917
- asthma7,162
- cough6,754
- drug ineffective6,733
- fatigue5,387
- product dose omission issue5,192
- headache5,109
- off label use4,989
- wheezing4,443
- nausea4,250
- pneumonia4,099
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 280 |
| 2005 | 92 |
| 2006 | 73 |
| 2007 | 99 |
| 2008 | 345 |
| 2009 | 162 |
| 2010 | 191 |
| 2011 | 353 |
| 2012 | 496 |
| 2013 | 540 |
| 2014 | 665 |
| 2015 | 1,285 |
| 2016 | 2,554 |
| 2017 | 2,172 |
| 2018 | 2,274 |
| 2019 | 2,978 |
| 2020 | 6,335 |
| 2021 | 8,280 |
| 2022 | 9,922 |
| 2023 | 12,958 |
| 2024 | 15,218 |
| 2025 | 15,160 |
| 2026 | 11,094 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,960,633 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device delivery system issueSignal | 8,121 | 94.4 | 92.0 | 528,572 |
| drug dose omission by deviceSignal | 7,917 | 25.2 | 24.6 | 165,853 |
| wheezingSignal | 4,443 | 18.1 | 17.6 | 66,705 |
| asthmaSignal | 7,162 | 15.1 | 14.8 | 89,109 |
| wrong technique in product usage processSignal | 11,012 | 12.9 | 12.6 | 115,060 |
| no adverse eventSignal | 8,682 | 11.3 | 11.0 | 78,006 |
| dyspnoeaSignal | 13,701 | 5.6 | 5.5 | 51,286 |
| coughSignal | 6,754 | 5.5 | 5.4 | 24,754 |
| product dose omission issueSignal | 5,192 | 4.0 | 3.9 | 11,752 |
| pneumoniaSignal | 4,099 | 2.9 | 2.8 | 5,010 |
| headache | 5,109 | 1.8 | 1.8 | 2,000 |
| fatigue | 5,387 | 1.6 | 1.5 | 1,116 |
| off label use | 4,989 | 1.3 | 1.2 | 323 |
| nausea | 4,250 | 1.2 | 1.2 | 158 |
| drug ineffective | 6,733 | 1.1 | 1.1 | 139 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.